Oxford Immune Algorithmics

In the fight against cancer, as highlighted in a recent Time article, the emotional toll of diagnosis and treatment is often overlooked. Globally, over 27% of cancer patients suffer from depression, and this figure increases every year. This mental distress not only impacts their quality of life but also affects adherence to treatment plans.   https://bit.ly/40pYUTC   Cancer patients often experience a significant burden throughout the course of their treatment. Frequent doctor’s visits, can turn into a seemingly endless cycle of appointments that disrupt daily life. The repeated blood draws and collections—critical for monitoring treatment effectiveness—can become physically uncomfortable and emotionally taxing, leaving patients feeling like their bodies are under constant scrutiny. Waiting at labs consumes valuable time, creating additional strain as patients juggle work, personal responsibilities, and the emotional weight of their diagnosis. Meanwhile, the anxious period spent anticipating test results can heighten stress levels, exacerbating an already challenging journey. Collectively, these factors underscore the substantial toll that cancer treatments and related medical processes can take on individuals and their families. Artificial intelligence (AI) is emerging as a game-changer, offering tools that simplify complex decisions, reduce uncertainty, and support patients and doctors. AI-enabled diagnostics can analyse vast datasets and deliver personalised information. This approach empowers doctors to make precise recommendations, helping patients navigate their treatment with confidence.   Moreover, early diagnosis powered by AI can prevent invasive and painful procedures, transforming healthcare from a corrective to a preventive approach. By identifying risks and tailoring treatments at the earliest stages, patients gain not only better outcomes but also a less distressing and more efficient path to recovery.    Algocyte®, developed by Oxford Immune Algorithmics® (OIA), is a set of AI causal-driven solutions that enable remote digital endpoints in healthcare pathways to understand health and disease based on adaptive, personalised and precision blood testing.   At OIA, we have always thought that the best AI is one that does not need explanation because it simply makes patient's and clinician's lives easier.    Oxford Immune Algorithmics® is a deep-tech start-up associated to UK's Golden Triangle, the University of Oxford, the University of Cambridge and King's College London that applies Artificial General Intelligence (hybrid causal predictive & generative AI) based on symbolic regression and program synthesis to deliver decentralised mission-driven solutions to everyone today.   #futurehospital #HealthcareInnovation #EarlyDetection #biotechnology #biotech #PrecisionMedicine #DigitalHealth #PreventativeCare #AGI #AI #artificialintelligence #precisionhealthcare #predictivemedicine #PersonalisedHealth #SavingLives

I am happy to share that Prof. Andy Adamatzky's edited volume P̳o̳s̳t̳-̳A̳p̳o̳c̳a̳l̳y̳p̳t̳i̳c̳ ̳C̳o̳m̳p̳u̳t̳i̳n̳g̳, has been released by World Scientific Publishing Press featuring a chapter I contributed with titled '𝑾𝒉𝒂𝒕 𝒕𝒐 𝑪𝒐𝒎𝒑𝒖𝒕𝒆 𝑩𝒆𝒇𝒐𝒓𝒆 𝒂𝒏 𝑨𝒑𝒐𝒄𝒂𝒍𝒚𝒑𝒔𝒆: 𝑲𝒏𝒐𝒘𝒍𝒆𝒅𝒈𝒆 𝒂𝒔 𝑪𝒓𝒚𝒑𝒕𝒐𝒄𝒖𝒓𝒓𝒆𝒏𝒄𝒚 𝒂𝒕 𝒕𝒉𝒆 𝑬𝒏𝒅 𝒐𝒇 𝑪𝒊𝒗𝒊𝒍𝒊𝒔𝒂𝒕𝒊𝒐𝒏' that (almost) opens the book after Prof. JF Costa who I greatly admire. Contributions from other highly esteemed colleagues that wrote out-of-the-box-thinking chapters pushed by the eccentric topic exploring the basics and the priorities for computing at the civilisation level. A 450-page tour de force on what is important at our current peak in computing power and human faculty. Is it chatbots, highly polluting crypto? How to make these innovative technologies better or useful to create and preserve knowledge? And for what purpose? 𝐂𝐨𝐧𝐭𝐞𝐧𝐭𝐬: ▻ The Clock of the Apocalypse: The Rhythms of Life and the Ending of Time (J F Costa and P Gouveia) ▻ What to Compute Before an Apocalypse: Knowledge as Cryptocurrency at the End of Civilisation (H Zenil) ▻ Evolutionary Techniques in Analyzing Thom's Catastrophes: Insights into Complex System Collapses (I Zelinka) ▻ Computing with Stones and Sticks (J Gorecki) ▻ Computing without Electronics (A Adamatzky) ▻ Post Apocalyptic Computing and Technology: Towards Computing from ▻ Natural Colloids and Micro-Fragments (A Chioleri, M Crepaldi, D Torazza, Noushin Raeisi Kheirabadi and A Adamatzky) ▻ Analog Computation after Apocalypsis (B Ulmann) ▻ Computing with Clocks (J Edwards, A Yakovlev and S O'Keele) ▻ Bio-inspired Fault-tolerance in Electronic Systems (Martin A Trefzer) ▻ Before and After Big Crunch in a Reversible Discrete Cellular Universe (Kenichi Morita) ▻ Post-Apocalyptic Computing from Cellular Automata (G J. Martinez, A Adamatzky and G Chen) ▻ Smoke Signals to Silicon: Unraveling the Threads of Emerging Computing ▻Paradigms (I K. Chatzipaschalis, I-AnAgelos Fyrigos and G Ch. Sirakoulis) ▻ Towards Computational Apocalypse: Computing with Minimal Resources and Earth-Abundant Materials (L Alluhaibi, Pier Luigi Gentili, W Głąb, E Kowalewska, S Pecqueur, K Pilaka, A Pritam, A Sławek and K Szaciłowski) ▻ Challenges of Unconventional Computing: A Personal Perspective (G Owen) ▻ Self-Decomputing: The Lack of Meaning among Information (J Vallverdú) ▻ A Metaphysical Approach to the Apocalypse to Come (C Pombo Nabais) ▻ Listen (H Ritz, E Montero, F Moon and B Baylor) ▻ The Buddha and Biomass (A Schumann) ▻ Neosentience Production and a Set of Conversations with ChatGPT ▻ Exploring Speculative Post-Apocalyptic Questions (B Seaman) ▻ Doomsday Machines: Computer and Computing in Cold-War Science Fiction (S Höltgen) https://lnkd.in/eufvEa7H The book is expensive but I will be happy to share a preprint of my contribution and probably others will do too.

𝐍𝐨 𝐋𝐚𝐫𝐠𝐞 𝐋𝐚𝐧𝐠𝐮𝐚𝐠𝐞 𝐌𝐨𝐝𝐞𝐥 𝐖𝐢𝐥𝐥 𝐑𝐢𝐯𝐚𝐥 𝐚 𝐏𝐡𝐃 𝐀𝐧𝐲 𝐓𝐢𝐦𝐞 𝐒𝐨𝐨𝐧—𝐇𝐞𝐫𝐞’𝐬 𝐖𝐡𝐲 Social media seems to have forgotten that we had already been sold the idea that OpenAI’s earlier model (#o1) had achieved “PhD-level intelligence,” heralded by Mira Murati, OpenAI’s Chief Technology Officer. A Newsweek article even implied that OpenAI tools had already surpassed PhD-level performance. I think #LLMs are impressive tools but what surprises me the most is how much of human behaviour can be reproduced with relatively simplistic statistical approaches with ever increasing data & computing resources. We suspected that human language & intelligence were somehow disconnected by way of politicians, but LLMs have given us proof. The social media frenzy about OpenAI's tools has made me realise that what we have accused LLMs for, we can also accuse humans for, We Are The Parrots. With online 'science' influencers amplifying every OpenAI marketing effort ad nauseum (I hope they get paid 😊). As someone who has gone through the torture of earning two #PhDs some time ago, and supervises PhD students today, I can say that earning a doctoral degree is about much more than simply supplying answers. It involves hard work, commitment, an in-depth review of the state of the art in a specific field from reliable sources, which LLMs, including o1 and likely #o3 have traditionally got very wrong. But crucially, a PhD is less about finding answers and more about asking questions, an innately human endeavour driven by curiosity, persistence, and the motivation to challenge established knowledge and solve very human problems. No current AI—whether o1, o3, or future iterations—can spontaneously replicate such drives, as they only act upon prompts rather than harbouring any intrinsic impetus of their own which is the very essence of a PhD. This doesn’t mean I’m sceptical about the potential for machine intelligence. Far from it: I’m a strong advocate for AI and even ASI (Artificial #Superintelligence), although I’m more measured when it comes to the often ill-defined concept of #AGI (Artificial General Intelligence). Nor do I subscribe to the idea that human intelligence is the ultimate benchmark, which I think is overrated after finding who the parrots really are. Rather, my point is a straightforward one: comparing any LLM to a #PhD graduate is a flawed analogy. While LLMs can undoubtedly assist with generating questions and guiding inquiry, they do so only at our behest. Without their own agenda—lacking historical, biological, or personal motivations—these systems are not remotely close to embarking on a quest for knowledge in the way a doctoral researcher does. LLMs are impressive tools but instruments that should help achieve very human goals—rather than inquisitive minds embarking on their intellectual journeys as the analogy to PhDs may wrongly suggest. #MachineLearning #ASI #PhDLevelAI #OpenAI #FutureOfAI #CriticalThinking

Hopefully 2025 may bring a bit more common sense and diversity to the debates around AI, as Hector Zenil Oxford Immune Algorithmics touches on in Trevor Clawson's article. Certainly there is some value in LLM models but will it deliver the ROI valuations in 2024 suggest? In fields such as precision medicine it is doubtful conversational AI has all the answers...https://bit.ly/40hbu7x #ai #genai #medtech #precisionmedicine #innovation

Oxford Immune Algorithmics (OIA) and Dr. Hector Zenil featured on Forbes In a recent article, Trevor Clawson from Forbes cites and features OIA and our founder on 𝐇𝐨𝐰 𝐔.𝐊. 𝐒𝐭𝐚𝐫𝐭𝐮𝐩𝐬 𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐞𝐝 𝐀 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐘𝐞𝐚𝐫 "A breakdown of the figures suggested Artificial Intelligence was a bright spot, but according to Dr. Hector Zenil, founder and Chief Visionary Officer at Oxford Immune Algorithmics, investment has been focused on certain segments of the AI universe at the expense of others.   “The biggest challenge has been the extreme concentration of investment in large language models (LLMs) and chatbots,” Dr. Zenil says.   "As he sees it, this has diverted funding away from other promising areas of investment, making it more difficult to raise capital. The solution? Oxford Immune Algorithmics applies AI to predictive medicine and has developed a platform to provide an analysis of patient health. Dr Zenil says the company’s pitch to investors emphasises the value proposition and the prospects of returns.   “We're emphasizing the tangible impact and near-term ROI of our value proposition, differentiating ourselves from the speculative nature of current LLM investments,” Dr. Zenil says. At OIA, we believe that AI should serve to tackle human's greatest challenges today, from cancer to chronic inflammation to antibiotic resistance to shortages of clinical staff to healthcare inequality. Algocyte®, developed by Oxford Immune Algorithmics® (OIA), is a set of AI causal-driven solutions different to simple pattern-matching based on the foundations of AGI that enable remote digital endpoints in healthcare pathways to understand health and disease based on adaptive, personalised and precision blood testing.   Oxford Immune Algorithmics® is a deep-tech start-up associated to UK's Golden Triangle, the University of Oxford, the University of Cambridge and King's College London that applies Artificial General Intelligence (hybrid causal predictive & generative AI) based on symbolic regression and program synthesis to deliver decentralised mission-driven solutions to everyone today. #Forbes #HealthcareInequality #futurehospital #HealthcareInnovation #EarlyDetection #biotechnology #biotech #biology #science #PrecisionMedicine #DigitalHealth #PreventativeCare #AGI #AI #artificialintelligence #precisionhealthcare #predictivemedicine #PersonalisedHealth #SavingLives

𝐀 Harvard University 𝐠𝐫𝐨𝐮𝐩 𝐚𝐧𝐝 𝐃𝐫. Eric Topol, MD'𝐬 𝐢𝐧𝐭𝐞𝐫𝐩𝐫𝐞𝐭𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞𝐢𝐫 𝐍𝐚𝐭𝐮𝐫𝐞 𝐩𝐚𝐩𝐞𝐫 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐞𝐬 𝐀𝐥𝐠𝐨𝐜𝐲𝐭𝐞'𝐬 𝐚𝐧𝐝 𝐎𝐱𝐟𝐨𝐫𝐝 𝐈𝐦𝐦𝐮𝐧𝐞 𝐀𝐥𝐠𝐨𝐫𝐢𝐭𝐡𝐦𝐢𝐜𝐬 (𝐎𝐈𝐀)'𝐬 𝐦𝐚𝐢𝐧 𝐯𝐚𝐥𝐮𝐞 𝐩𝐫𝐨𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧.   Traditional blood testing often relies on standard reference ranges based on population averages to inform clinicians and patients, but new clinical results published this month in 𝘕𝘢𝘵𝘶𝘳𝘦 journal show that individuals have unique features that effectively act like 𝐡𝐞𝐚𝐥𝐭𝐡 𝐟𝐢𝐧𝐠𝐞𝐫𝐩𝐫𝐢𝐧𝐭𝐬. The new study shows that these personalised benchmarks can significantly improve early disease detection by providing a better and more precise picture of an individual health.   The clinical world seems to be catching up with OIA's value proposition based on our research leading to the development of Algocyte.  Algocyte compares a user blood test results to their own historical data, rather than to generic population averages from which clinicians can identify subtle changes that may indicate early stages of conditions or diseases such as diabetes, chronic inflammation or heart disease. Algocyte effectively instantiates a solution based on these findings and represents a step towards population-scalable precision medicine, offering tailored care based on individual biology and common blood markers, particularly a Complete Blood Count (CBC), the most common blood test which is related to the immune system. 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐢𝐭 𝐨𝐧 𝐨𝐮𝐫 𝐛𝐥𝐨𝐠 𝐩𝐨𝐬𝐭: https://lnkd.in/gWmDiS-b   Algocyte®, developed by Oxford Immune Algorithmics® (OIA), is a set of AI causal-driven solutions that enable remote digital endpoints in healthcare pathways to understand health and disease based on adaptive, personalised and precision blood testing.   Oxford Immune Algorithmics® is a deep-tech start-up associated with UK's Golden Triangle, the University of Oxford, the University of Cambridge and King's College London that applies Artificial General Intelligence (hybrid causal predictive & generative AI) based on symbolic regression and program synthesis to deliver decentralised mission-driven solutions to everyone today.   #futurehospital #futureofbloodtesting #smartbloodtesting #HealthcareInnovation #EarlyDetection #biotechnology #biotech #biology #science #PrecisionMedicine #DigitalHealth #PreventativeCare #AGI #AI #artificialintelilgence #precisionhealthcare #predictivemedicine #PersonalisedHealth #BloodTests

🎉 We are celebrating a three-year winning streak at New Scientist Live! Our Hospital of the Future exhibit was recognised by the public as the most popular feature at the event for the third year in a row. Congratulations to our 150+ volunteers who made it happen! Read more: https://lnkd.in/dMSAuGmP

Recently, the journal Nature published an article titled "Ultra-precise 3D Cartography of Cancer Cells Unveils Secrets of Tumour Geography". This work details how three-dimensional cartography of tumour cells, analysing their position and biology, is providing new insights into the geography of cancer. The findings reveal how the spatial organisation of cells influences the progression of various types of cancer. These advances represent a significant step towards precision medicine, enabling more specific and effective interventions in cancer treatment. https://lnkd.in/dAZZA9_Z   The article is part of a series of 12 studies published by the Human Tumor Atlas Network (HTAN), which analysed hundreds of thousands of cells from human and animal tissues. These studies provide a three-dimensional view of the tumour microenvironment, shedding light on the interactions between tumours and the immune system.   Algocyte®, developed by Oxford Immune Algorithmics®, is a set of AI causal-driven solutions that enable remote digital endpoints in healthcare pathways to understand health and disease. Algocyte® monitors key and complex common blood markers that keep us healthy advancing predictive medicine that will change sick population-wide care to precision personalised healthcare.   Oxford Immune Algorithmics® is a University of Oxford deep-tech start-up associated to University of Cambridge and King's College London that applies Artificial General Intelligence (hybrid causal predictive & generative AI) based on symbolic regression and program synthesis to deliver decentralised mission-driven solutions to everyone today.   #HealthcareInnovation #EarlyDetection #biotechnology #biotech #biology #science #PrecisionMedicine #DigitalHealth #PreventativeCare #AGI #AI #artificialintelilgence #precisionhealthcare #predictivemedicine

We celebrated with our traditional end-of-year dinner and this time a Masterclass in Dim Sum cooking at the Din Tai Fung UK in London another year of hard work dedicated to bringing #innovation to #healthcare to improve the lives of #patients and #healthconsumers. OIA wishes to thank our staff (local and around the world, with some coming even from Egypt), collaborators, investors, and shareholders, without whom we could not bring our groundbreaking deep tech to the market and who have continuously supported the company for years. Early next year, OIA will share major announcements on the deployment of our technology and medical instrument in clinical environments at top institutions, as well as new developments in investment and strategic partnerships as we diversify our access to funding markets. Developed by Oxford Immune Algorithmics®, Algocyte® is founded on more than 15 years of our founder Dr. Hector Zenil’s research into complexity science for AI applied to cellular and molecular biology. Algocyte® offers an end-to-end turnkey suite of causality-driven AI solutions that enable remote digital endpoints within healthcare pathways, providing deeper insights into health and disease. Algocyte® monitors and understands key and complex common blood markers that keep each of us healthy to advance predictive medicine aimed at changing sick population-wide care to precision healthcare. Algocyte® helps find prescription gaps with its differential diagnosis hypothesis engine and enables remote medicine pathways for wider deployment of cutting-edge personalised drug treatment with its remote blood testing and machine learning capabilities beyond current simple pattern-matching. Oxford Immune Algorithmics® is a University of Oxford deep-tech start-up associated to University of Cambridge and King's College London that applies Artificial General Intelligence (hybrid causal predictive & generative AI) based on symbolic regression and program synthesis beyond simple pattern-matching to deliver decentralised mission-driven solutions to everyone today. Michelle Lea Hugo Phillips Kourosh Saeb-Parsy Imad Alabed Steven T. Mariana Castellon Santiago Zenil Araiza Kaye Ashley Buenafe Oksana Josypcuk Chiu Ho YU M A Motin Sobuj Santiago Hernandez Orozco Huda Khan Sultan Khan Allan Bezanson John Cullen Roger W. Ferguson, Jr. Mark Stevenson John Iannuccillo Pamela Winsor Oxford University Innovation Susan Bisaillon Luc Bowie Brad White Jesper Tegner Mario Alberto Mercado Sanchez Md.Rashedul Amin Daniel Mannion Franklin Hernández Paz Luan Ozelim Alberto Espinosa Zerhio Zenil Yash Shukla #HealthcareInnovation #EarlyDetection #biotechnology #biotech #PrecisionMedicine #DigitalHealth #PreventativeCare #AGI #AI #artificialintelligence #precisionhealthcare #predictivemedicine #causality

Understanding causality is essential for advancing science. A recent paper introduced an algorithm that maps causal relationships in complex systems, uncovering unique, synergistic, or redundant interactions between multiple variables. https://lnkd.in/gCExnbt5   While the paper contributes with an approach to dealing with multiple variables rather than the traditional pairwise, it relies on correlation based on Shannon entropy only. The world of science is barely catching up with perturbation analysis as introduced in the 1980s to advance the field of causality but it still relies on statistical tools developed in the 1940s. This paper makes some progress dealing with more complex systems that depend on multiple variables that can be combined with other model-driven approaches.    Algocyte®, developed by Oxford Immune Algorithmics, is a set of AI causal-driven solutions that enable remote digital endpoints in healthcare pathways to understand health and disease. Algocyte® monitors key and complex common blood markers that keep us healthy advancing predictive medicine that will change sick population-wide care to precision personalised healthcare.   Oxford Immune Algorithmics is a University of Oxford deep-tech start-up associated to Cambridge University and King's College London that applies Artificial General Intelligence (hybrid causal predictive & generative AI) based on symbolic regression and program synthesis to deliver decentralized mission-driven solutions to everyone today.   #HealthcareInnovation #EarlyDetection #biotechnology #biotech #biology #science #PrecisionMedicine #DigitalHealth #PreventativeCare #AGI #AI #artificialintelilgence #precisionhealthcare #predictivemedicine #Causality